Cure My Disease

Don't miss your cure!

 Log in / Sign up

Why are people with this rare bone disorder prone to diabetes?

NCT ID NCT03761290

Knowledge-focused Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study aims to understand why people with pseudohypoparathyroidism type 1A (PHP1A) have a higher risk of type 2 diabetes. Researchers will measure insulin sensitivity and beta-cell function in 14 participants with PHP1A or related conditions, comparing them to matched healthy controls. The study was terminated early, so results may be limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal why type 2 diabetes is more common in people with PHP1A, pointing toward future prevention or treatment strategies.
What could go wrong
This is a small, terminated pilot study with only 14 participants, so results may be limited and not generalizable. No direct treatment is being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

14 people

The number who actually took part.

Started

Jun 2019

Finished

Apr 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with PHP1A/PPHP and matched controls

Ages

6 to 50 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of PHP1A/PPHP 2. Age between 6 and 50 years old Controls will be matched based on: 1. Gender 2. Race 3. Age (±2 years if \<25 years old or ±5 years if ≥25 years old) 4. BMI (±2 kg/m2) 5. Diabetes status Exclusion Criteria: 1. Treatment with appetite-altering drug or initiation of a new weight loss program in the past 3 months 2. Type 1 diabetes 3. Type 2 diabetes treated with insulin or GLP-1 receptor agonists or A1c \>9%at their most recent clinic visit 4. Pregnant or lactating women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Albright hereditary osteodystrophy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pseudohypoparathyroidism pseudohypoparathyroidism type 1A pseudopseudohypoparathyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Albright hereditary osteodystrophy Pseudohypoparathyroidism and pseudopseudohypoparathyroidism Pseudohypoparathyroidism type IA

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.